Clinical trials: Neuroendocrine Neoplasia's (NENs)
Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas.
- Conditions
- Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- PReCedeNT (NCT07185672)
- Testing
- Peptide Receptor Radionuclide Therapy with Lu177 DOTATATE, Capecitabine plus temozolamide
- Where
- 2 sites in India
- Volunteers
- 162 people
- Sponsor
- Tata Memorial Hospital
Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
The goal of this phase 0 proof-of concept study is to measure the therapeutic index (tumour to dose-limiting-organ dose ratios) of 161Tb-DOTA-LM3 in comparison to the current standard 177Lu-DOTATOC in the same…
- Trial name
- Beta plus (NCT05359146)
- Testing
- 161Tb-DOTA-LM3, 177Lu-DOTATOC
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- University Hospital, Basel, Switzerland